Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Liposomal Transcrocetin
- Development stage
- Phase 2
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Liposomal Transcrocetin (L-TC) is a drug designed to enhance tumor oxygenation, specifically addressing hypoxia, which is a significant factor contributing to radioresistance in tumors. By reoxygenating tumor cells, L-TC aims to improve radiosensitivity, thereby increasing the efficacy of radiotherapy and potentially leading to higher rates of pathological complete response (pCR) before surgery. It is administered as an intravenous infusion.
Beyond the preview
Go deeper on Liposomal Transcrocetin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Liposomal Transcrocetin.